Vertex Newswire

Comprehensive Real-Time News Feed for Vertex.

Results 1 - 20 of 211 in Vertex

  1. Senior Housing Properties Trust's (SNH) Management Discusses on Q4...Read the original story w/Photo

    22 hrs ago | Seeking Alpha

    ... of acquisitions, the vast majority of which was the trophy assets in the Boston Seaport innovation district lease to Vertex Pharmaceuticals for approximately $1.1 billion. The Vertex acquisition was transformative investment for SNH, which not only ...


  2. Alkermes Appoints R&D SVPRead the original story w/Photo

    Monday Feb 23 | Contract Pharma Breaking News

    ... R&D and drug discovery, most recently serving as senior vice president and interim global head of Research for Vertex Pharmaceuticals. He has built and led departments supporting the critical components of early pharmaceutical R&D, including ...


  3. Alkermes Appoints Senior Vice President of Research, Pharmaceutical and Nonclinical DevelopmentRead the original story w/Photo

    Monday Feb 23 | Pharmaceutical Processing

    ... drug discovery. Most recently, Dr. Namchuk served as Senior Vice President and Interim Global Head of Research for Vertex Pharmaceuticals, leading a group of more than 450 researchers in the discovery of transformational medicines in the areas of ...


  4. Lysosomal Therapeutics to use $20M to develop, test Parkinson's drugRead the original story w/Photo

    Friday Feb 20 | Business Journal

    ... of the funding accompanied an announcement that Darren Braccia, previously senior director of business development at Vertex Pharmaceuticals , was appointed vice president of business development. He will lead external collaboration efforts and ...


  5. SolarEdge files for $125M IPO on the back of growth of solar gearRead the original story w/Photo

    Thursday Feb 19 | GigaOM

    ... ebt from investors including Opus Capital Venture Partners , ORR Partners, Genesis Partners , Pacven Walden Ventures, Vertex, Norwest Venture Partners and Lightspeed Venture Partners.


  6. Pharmacyclics, Inc. Reports Fourth Quarter And Full Year 2014...Read the original story

    Tuesday Feb 17 | BioSpace

    ... entitled, "Bench to Bedside: From PCI-32765 to ibrutinib to IMBRUVICA.Dav" Past recipients of this award include Vertex Pharmaceuticals for its work in hepatitis C, Genentech on behalf of Avastin, and Novartis for its development of Glivec, among ...


  7. Surprise! We Still Need Drugmakers to Develop Revolutionary Hepatitis C DrugsRead the original story w/Photo

    Tuesday Feb 17 | The Motley Fool

    ... a whopping 27% of patients stopped taking their medicine prior to completing the regimen. The FDA's 2011 approval of Vertex Pharmaceuticals ' Incivek improved cure rates to 80% and cut treatment duration to 24 weeks; however, since peginterferon and ...


  8. Agios Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial ResultsRead the original story

    Monday Feb 16 | BioSpace

    ... McLaughlin as vice president of human resources. Megan was senior vice president of corporate communications at Vertex Pharmaceuticals. She served on their senior management team, where she led global corporate and employee communications programs ...


  9. Could This Be The Biggest Advance in Hepatitis C since Gilead Sciences' Sovaldi?Read the original story w/Photo

    Monday Feb 16 | The Motley Fool

    ... of patients, and came with a host of side effects. In 2011, treatment took a huge step forward when the FDA approved Vertex Pharmaceuticals ' Incivek, a therapy that cured 80% of patients over a 24 week time period. However, Incivek was still far ...


  10. In Case You Missed It, There's a New Fastest Growing Drug in the WorldRead the original story w/Photo

    Saturday Feb 14 | The Motley Fool

    Ladies and gentlemen, for the third time in less than four years we've witnessed the fastest growing drug in the world get unseated. A walk down memory lane As a refresher, in May 2011, the Food and Drug Administration approved a revolutionary new pill from Vertex Pharmaceuticals known as Incivek to treat hepatitis C. The previous standard of care for HCV, a disease that affects an estimated 3.2 million people in the U.S. and 180 million worldwide and which can lead to a number of serious liver complications and death over the long term, had been a combination of interferon and ribavirin.


  11. Vertex Pharmaceuticals Incorporated To Present At Upcoming Investor ConferencesRead the original story

    Wednesday Feb 11 | BioSpace

    Vertex Pharmaceuticals Incorporated today announced that it will present at the RBC Capital Market Healthcare Conference in New York, NY on Tuesday, February 24th at 11:30 a.m. ET.


  12. AMRI hires new chief information officerRead the original story w/Photo

    Thursday Feb 12 | Business Journal

    Wang, who took the job Monday, is managing the technology iniatiatives and informaiton technology at the Albany, New York drug developer with about 1,300 total employees. Wang has 25 years in managing technology innovations at a range of companies, including most recently as senior vice president and chief information officer at OPKO Health Inc. Before that, he worked for Vertex Pharmaceuticals and Teva Pharmaceuticals .


  13. Vertex to Present at Upcoming Investor ConferencesRead the original story

    Wednesday Feb 11 | Freshnews

    Vertex Pharmaceuticals Incorporated today announced that it will present at the RBC Capital Market Healthcare Conference in New York, NY on Tuesday, February 24th at 11:30 a.m. ET. Vertex will also present at the Cowen and Company Healthcare Conference in Boston, MA on Tuesday, March 3rd at 10:40 a.m. ET.


  14. Skanska Looks For The Next Vertex At 121 SeaportRead the original story

    Friday Feb 6 | Banker & Tradesman

    ... of Skanska USA Development, said 121 Seaport has a shot at attracting the neighborhood's next big lab tenant. Vertex Pharmaceuticals was the first major life science company to commit to the South Boston waterfront, moving from Cambridge to a ...


  15. Arkansas Reaches Settlement in Cystic Fibrosis Drug SuitRead the original story

    Thursday Feb 5 | WRKO-AM Brighton

    Arkansas Medicaid officials have reached a legal settlement to resolve claims the state denied patients an expensive cystic fibrosis therapy made by Vertex Pharmaceuticals because of its cost.


  16. Former Harley Davidson CEO, Rich Teerlink to Retire from Vertex Board of DirectorsRead the original story

    Wednesday Feb 4 | Information Technology

    Inc., the leading provider of corporate enterprise tax solutions and services, announced today that after 13 years of distinguished service on the Vertex Board of Directors, Rich Teerlink will retire effective February 4, 2015. Teerlink joined the Vertex Board in 2002, shortly after his retirement as Chairman and CEO of Harley Davidson, where he enjoyed great success over his 18-year tenure.


  17. 3 Stocks Hedge Funds Just Bought; Should You?Read the original story

    Wednesday Feb 4 | Insider Monkey

    ... VOLC ), which they have built up to 9.81%. During the third quarter of 2014 they also opened new positions in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) and GlaxoSmithKline plc (ADR) (NYSE: GSK ). Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has ...


  18. Vertex Pharmaceuticals (MA) Learns From Gilead Sciences, Inc.'s...Read the original story

    Sunday Feb 1 | BioSpace

    As Vertex Pharmaceuticals looks ahead to a launch this year of a cystic fibrosis drug that could treat 10 times as many patients as its current drug, it appears to be taking a lesson from the backlash in early 2014 against hepatitis C drug, Sovaldi. On a conference call with analysts this week to discuss its fourth-quarter and full-year financial results, Vertex Chief Commercial Officer Stuart Arbuckle outlined the company's plans for lumacaftor, which is expected to be approved in the U.S. by July 5 and in Europe sometime toward the end of the year.


  19. Vertex Pharmaceuticals (MA)'s CEO Believes $215 Million Plan Would Mean Better New DrugsRead the original story

    Sunday Feb 1 | BioSpace

    Obama's $215 Million Plan Would Mean Better New Drugs "> February 2, 2015 By Alex Keown , Breaking News Staff BOSTON -- Jeffrey Leiden , Vertex Pharmaceuticals CEO, said President Barack Obama 's $215 million proposed Precision Medicine Initiative will spur the development of new medications that will change the lives of patients for the better. In an interview with the Boston Business Journal , Leiden , who did not attend the Washington D.C. event, touted the proposal to create a national database of genetic, microbial and lifestyle information of over one million patients to learn how to individualize care.


  20. Vertex Should Expect Approvals For Its Cystic Fibrosis MedicationsRead the original story w/Photo

    Monday Feb 2 | Seeking Alpha

    ... the most common CF mutation should also be enough for approval. This will triple the current addressable CF market. Vertex Pharmaceuticals (NASDAQ: VRTX ) is a large (market cap of $26.49 billion) global biotechnology company with clinical ...